ArticleRevista espanola de cardiologia (English ed.)2020
Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project.
Article in Revista espanola de cardiologia (English ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03718273 (A Phase III Clinical Trial to Compare Ivabradine Versus Digoxin in the Heart Rate Control in Patients With Permanent Atrial Fibrillation Under Treatment With Beta-blockers or Calcium Antagonists.), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Clinical Trial to Compare Ivabradine Versus Digoxin in the Heart Rate Control in Patients With Permanent Atrial Fibrillation Under Treatment With Beta-blockers or Calcium Antagonists.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation.Indian heart journalTrial
- Therapeutic Use and Molecular Aspects of Ivabradine in Cardiac Remodeling: A Review.International journal of molecular sciences · 2023Review
- Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system.Frontiers in pharmacology · 2023Article
- A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure.European heart journal. Case reports · 2022Article
- The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels.Frontiers in pharmacology · 2022Article
- Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?Journal of clinical medicine · 2021Review
- Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review.Diagnostics (Basel, Switzerland) · 2021Review
- [Do we have a new drug for heart rate control in patients with permanent atrial fibrillation? Response].Revista espanola de cardiologia · 2020Article
- Do we have a new drug for heart rate control in patients with permanent atrial fibrillation? Response.Revista espanola de cardiologia (English ed.) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectivesIvabradine is an inhibitor of the If channel, the main determinant of the pacemaker function of the sinus node. The drug has been approved for the treatment of angina and heart failure. There is some evidence of its role as an inhibitor of atrial-ventricular node (AVN) conduction. The aim of the BRAKE-AF project is to assess ivabradine use for rate control in atrial fibrillation (AF).
methodsA multicenter, randomized, parallel, open-label, noninferiority phase III clinical trial will be conducted to compare ivabradine vs digoxin in 232 patients with uncontrolled permanent AF despite beta-blockers or calcium channel blockers. The primary efficacy endpoint is the reduction in daytime heart rate measured by 24-hour Holter monitoring at 3 months. This clinical trial will be supported by an electrophysiological study of the effect of ivabradine on the action potential of the human AVN. To do this, an experimental model will be used with Chinese hamster ovarium cells transfected with the DNA encoding the expression of the t channels involved in this action potential and recording of the ionic currents with patch clamp techniques.
resultsNew data will be obtained on the effect of ivabradine on the human AVN and its safety and efficacy in patients with permanent AF.
conclusionsThe results of the BRAKE-AF project might allow inclusion of ivabradine within the limited arsenal of drugs currently available for rate control in AF. CLINICAL
trial registrationhttp://www.clinicaltrials.gov. Identifier: NCT03718273.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.